Laura Jacobsen, MD : Research

This is a Phase 2b, investigator* and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

Investigator

Laura Jacobsen

Status

Accepting Candidates

Ages

5 Years - 40 Years

Sexes

All

T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all…

Investigator

Laura Jacobsen

Status

Accepting Candidates

Ages

6 Years - 35 Years

Sexes

All

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

Investigators

Laura Jacobsen, Michael J Haller

Status

Accepting Candidates

Ages

12 Years - 35 Years

Sexes

All